Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
06/05/202115:01Business WireAcceleron Reports First Quarter 2021 Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
29/04/202106:24Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
29/04/202106:10Business WireAcceleron Announces First Quarter 2021 REBLOZYL® Net SalesNASDAQ:XLRNAcceleron Pharma Inc
26/04/202106:00Business WireAcceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021NASDAQ:XLRNAcceleron Pharma Inc
22/04/202115:11Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XLRNAcceleron Pharma Inc
22/04/202115:08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XLRNAcceleron Pharma Inc
21/04/202115:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
05/04/202106:00Business WireAcceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH)...NASDAQ:XLRNAcceleron Pharma Inc
01/04/202106:00Business WireNew England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arter...NASDAQ:XLRNAcceleron Pharma Inc
25/02/202115:13Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XLRNAcceleron Pharma Inc
25/02/202115:01Business WireAcceleron Reports Fourth Quarter and Full Year 2020 Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
23/02/202106:00Business WireAcceleron to Participate in Two Upcoming Healthcare Investor ConferencesNASDAQ:XLRNAcceleron Pharma Inc
17/02/202106:00Business WireAcceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021NASDAQ:XLRNAcceleron Pharma Inc
16/02/202111:34Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
16/02/202106:37Business WireHealth Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndr...NASDAQ:XLRNAcceleron Pharma Inc
04/02/202106:10Business WireAcceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net SalesNASDAQ:XLRNAcceleron Pharma Inc
04/01/202106:00Business WireAcceleron to Participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021NASDAQ:XLRNAcceleron Pharma Inc
14/12/202006:00Business WireAcceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (P...NASDAQ:XLRNAcceleron Pharma Inc
01/12/202006:00Business WireAcceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic SclerosisNASDAQ:XLRNAcceleron Pharma Inc
13/11/202009:01Business WireAcceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension ...NASDAQ:XLRNAcceleron Pharma Inc
13/11/202009:00Business WireAcceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hyperten...NASDAQ:XLRNAcceleron Pharma Inc
09/11/202006:00Business WireAcceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the...NASDAQ:XLRNAcceleron Pharma Inc
05/11/202015:15Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
05/11/202015:01Business WireAcceleron Reports Third Quarter 2020 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
05/11/202006:15Business WireAcceleron Announces Third Quarter 2020 REBLOZYL® Net SalesNASDAQ:XLRNAcceleron Pharma Inc
04/11/202015:01Business WireAcceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations at the 62nd American Society of Hematology Annual Me...NASDAQ:XLRNAcceleron Pharma Inc
26/10/202006:00Business WireAcceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020NASDAQ:XLRNAcceleron Pharma Inc
29/09/202005:59Business WireHealth Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Beta ThalassemiaNASDAQ:XLRNAcceleron Pharma Inc
17/09/202015:01Business WireAcceleron to Host Webcast Outlining the Design of Its Registrational Phase 3 STELLAR Trial of Sotatercept in Pulmonary Arteri...NASDAQ:XLRNAcceleron Pharma Inc
17/09/202008:13Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN